-p-500.jpg)
Surabaya – February 1st, 2026
Daewoong Pharmaceutical Indonesia (hereafter “Daewoong”) has officially launched its fixed-dose combination therapy for dyslipidemia in Surabaya, Indonesia’s second-largest city, following its initial introduction in Jakarta. This launch is significant as it expands specialized treatment solutions in East Java, where the prevalence of diabetes is notably high.
On February 1, Daewoong hosted the ‘Dyslipidemia Treatment Surabaya Regional Launch Symposium’ at Novotel Surabaya for approximately 100 local medical professionals. The event highlighted optimized LDL-C (low-density lipoprotein cholesterol) management strategies and shared the latest clinical insights on the dual-mechanism combination of Ezetimibe and Rosuvastatin.
Risk of cardiometabolic disease rises with diabetes…‘Early combination therapy’ for dyslipidemia discussed in East Java
The symposium featured in-depth discussions regarding high risk factors for cardiovascular metabolic diseases in East Java. According to the ‘Indonesia Health Survey (SKI 2023)’ by the Ministry of Health, Indonesia’s diabetes prevalence stands at 11.7%, exceeding the global average of 10.6%. East Java, in particular, is a key region with a large population of diabetes patients and high population density.
Dr. Soebagijo Adi Soelistijo, an endocrinologist at Dr. Soetomo Regional Public Hospital, emphasized, “When accompanied by diabetes, the risk of cardiovascular metabolic disease increases sharply, necessitating stricter cholesterol management”. He highlighted that “since statin monotherapy often has limitations in achieving LDL-C targets for diabetic patients, early combination therapy—which simultaneously inhibits both cholesterol synthesis and absorption to provide a powerful lowering effect—is an essential strategy”.
In addition, Dr. dr. Suryono, Chairman of the Indonesian Heart Association (PERKI) Surabaya, remarked, “In real-world clinical settings, treatment is often insufficient or inadequately controlled”. He evaluated that “Daewoong’s low-dose combination-based dyslipidemia treatment will play a crucial role in addressing complex cardiovascular metabolic disease challenges”.
Maximizing Treatment Efficiency with A Powerful Dual Mechanism… Superior LDL-C Lowering Effect Compared to Monotherapy
Daewoong’s treatment maximizes efficiency through the combined action of Rosuvastatin (inhibiting cholesterol synthesis in the liver) and Ezetimibe (inhibiting cholesterol absorption in the small intestine). A key feature is the ability to achieve a safer yet more powerful lowering effect even with relatively low doses.
Prof. Yudi Her Oktaviono, Head of Cardiology and Vascular Medicine at Dr. Soetomo Regional Public Hospital, stated, “Approximately 91.5% of coronary artery disease patients in Indonesia fail to reach the very-high-risk target of 55 mg/dL”. He added, “In this context, early combination therapy with proven efficacy is a rational strategy to bridge the treatment gap and dramatically improve patient prognosis”.
Establishing a Precise Prescribing Environment with Indonesia’s First ‘3-Dose Lineup Including Low-Dose’
Daewoong has established a comprehensive lineup of three dosage strengths (10/5 mg, 10/10 mg, and 10/20 mg), including Indonesia’s first 10/5 mg low-dose option. This allows for precise, personalized prescriptions based on an individual patient’s cardiovascular risk level. By offering a single-pill combination, it is expected to significantly improve convenience and treatment outcomes for patients with low medication adherence.
Baik In Hyun, Executive Director of Indonesia Business Division at Daewoong stated, “It is meaningful to introduce scientifically proven treatment options to medical professionals in East Java”. He concluded, “We will continue to strengthen cooperation with local medical societies to fulfill our responsibility as a healthcare partner dedicated to preventing cardiovascular disease and improving the quality of life for the Indonesian people”.